Chemotherapy in clear cell sarcoma
Chemotherapy in clear cell sarcoma
复制标题
DOI：
10.1007/s12032-010-9502-7
复制
发表时间：
2011-09-01
期刊：
影响因子：
3.4
通讯作者：
Judson, Ian R.
中科院分区：
文献类型：
--
作者：
Jones, Robin L.;Constantinidou, Anastasia;Judson, Ian R.
透明细胞肉瘤是一种罕见的易位相关肉瘤。很少有研究记录姑息性化疗治疗透明细胞肉瘤患者的反应率和无进展生存期。研究人员检索了两个转诊中心的前瞻性数据库，以确定接受化疗的透明细胞肉瘤患者。24例患者接受姑息性一线化疗，诊断时中位年龄为30岁。有18名男性和6名女性。1例（4%）达到部分缓解，9例（38%）病情稳定。14例（58%）患者治疗进展。中位无进展生存期为11周（95% CI， 3-20周）。开始一线化疗后的中位总生存期为39周（95% CI， 34-45周）。12例患者接受了二线化疗，其中11例（92%）进展，1例（8%）病情稳定。在接受三线化疗的5例患者中，4例（80%）进展，1例（20%）病情稳定。1例患者接受四线化疗，病情稳定4个月。传统化疗对透明细胞肉瘤的疗效最小，在本回顾性研究中，有效率为4%，中位无进展生存期为11周。这些数据为评估这种组织学亚型的新型药物的反应和结果提供了参考。
Clear cell sarcoma is a rare translocation-related sarcoma. There have been few studies documenting the response rate and progression-free survival in clear cell sarcoma patients treated with palliative chemotherapy. The prospectively maintained databases of two referral centres were searched to identify clear cell sarcoma patients treated with chemotherapy. Twenty-four patients were treated with palliative first-line chemotherapy with a median age of 30 years at diagnosis. There were 18 men and 6 women. One (4%) achieved a partial response and 9 (38%) had stable disease. Fourteen patients (58%) progressed on therapy. The median progression-free survival was 11 weeks (95% CI, 3-20 weeks). The median overall survival from commencing first-line chemotherapy was 39 weeks (95% CI, 34-45 weeks). Second-line chemotherapy was administered to 12 patients, 11 (92%) of these progressed and one (8%) had stable disease. Of the 5 patients treated with third-line chemotherapy, 4 (80%) progressed and one (20%) had stable disease. One patient received fourth-line chemotherapy and maintained stable disease for 4 months. Conventional chemotherapy has minimal activity in clear cell sarcoma as documented by the response rate of 4% and median progression-free survival of 11 weeks in this retrospective series. These data provide a reference for response and outcome in the assessment of novel agents in this histological subtype.